News Snapshot:
BENGALURU (REUTERS) - India's Hetero Labs said on Friday (July 9) it sought emergency use nod from the local regulator for Merck's Covid-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases. Molnupiravir is an antiviral drug being developed by Merck & Co and Ridgeback Biotherapeutics for the treatment of non-hospitalised Covid-19 patients. Merck tapped several Indian generic drugmakers between March and April, including Cipla and Dr Reddy's Laboratories, to expand the drug's production and conduct trials, hastening its availability in India to address a second wave of...
